BioMed X, Novo Nordisk Launch Oral Peptide Drug Delivery Collaboration

BioMed X, an independent biomedical research institute based in Heidelberg, Germany, launched a new collaboration with Novo Nordisk, a global healthcare company headquartered in Denmark. 

This partnership aims to address an efficient oral delivery of therapeutic peptides. A research team will be formed to work on this challenge with support from BioMed X and Novo Nordisk.

Despite advances in biomedical research, conventional oral peptide formulations continue to be limited by low intestinal permeability and rapid gastrointestinal transit. There is a need for innovative technologies that ensure prolonged retention of the dosage form in the lower small intestine, allowing for continuous release and efficient absorption.

The new project, named “Prolonged Retention of Oral Peptide Formulations in the Gut”, will be hosted at BioMed X in Heidelberg. 

It aims to develop novel oral formulation technologies that achieve site-specific, prolonged retention of tablets or capsules within the lower small intestine. The key objective is to significantly improve the absorption and bioavailability of peptide-based therapeutics.

The new research team will join the research community at BioMed X in Heidelberg, Germany. Researchers interested in becoming part of this new research group are invited to respond to this international call by submitting a project proposal via the BioMed X Career Space.

Dr. Christian Tidona, CEO of BioMed X, said,  “Making peptide drugs such as GLP-1 receptor agonists orally available via new formulation technologies will have a significant impact on patients’ lives. With our unique global crowdsourcing approach and our new partner Novo Nordisk, we are confident that we can drive innovation in oral formulation technologies to the next level.”